Historique
Périodique
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)
(Essai contrôlé randomisé de cabergoline, hydergine and levodopa/carbidopa dans le cadre de l'essai thérapeutique pour le traitement de la dépendance à la cocaïne (CREST) de Los Angeles)
Auteur(s) :
S. SHOPTAW ;
W. WATSON ;
C. REIBER ;
R. A. RAWSON ;
M. A. MONTGOMERY ;
M. D. MAJEWSKA ;
W. LING
Article en page(s) :
78-90
Sous-type de document :
N° spécial de revue / Special issue of a journal
Refs biblio. :
46
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Thésaurus mots-clés
COCAINE
;
DEPENDANCE
;
PHARMACOTHERAPIE
;
MEDICAMENTS
;
ESSAI THERAPEUTIQUE
;
PLACEBO
Note générale :
Addiction, 2005, 100, (Suppl. 1 Clinical Rapid Efficacy Screening Trials (CREST)), 78-90
Note de contenu :
graph. ; tabl.
Résumé :
ENGLISH :
Aim : This study tested three dopaminergic medications against a common unmatched placebo condition: hydergine 1 mg three times daily (n = 15); levodopa/carbidopa 25/100 mg three times daily (n = 15); cabergoline 0.5 mg per week (n = 15); and placebo three times daily (n = 15) as potential pharmacotherapies for cocaine dependence. Design : The four-parallel group, Cocaine Rapid Efficacy Screening Trial (CREST) design featured a 2-week baseline period followed by randomization to an 8-week medication condition that included 1 hour per week of cognitive behavioral drug counseling. A safety evaluation was conducted 4 weeks after termination. Measures : Outcomes included cocaine metabolites measured in urine, retention and self-reports for drug use, cocaine craving, clinical improvement, mood and HIV risk behaviors. Results : Participants assigned to receive cabergoline provided more urine samples negative for cocaine metabolites (42.4%) than those assigned to receive placebo (25.0%), a statistically significant difference after controlling for baseline differences in self-reported cocaine use (F = 2.95, df = 3; P = 0.05). Cabergoline-treated participants demonstrated a significant improvement over placebo from baseline to week 8 when measured using the Addiction Severity Index (ASI) employment subscale (overall change = {PRIVATE "TYPE=PICT;ALT=-"}0.09, SD = 0.10, t = 2.36, P
ENGLISH :
Aim : This study tested three dopaminergic medications against a common unmatched placebo condition: hydergine 1 mg three times daily (n = 15); levodopa/carbidopa 25/100 mg three times daily (n = 15); cabergoline 0.5 mg per week (n = 15); and placebo three times daily (n = 15) as potential pharmacotherapies for cocaine dependence. Design : The four-parallel group, Cocaine Rapid Efficacy Screening Trial (CREST) design featured a 2-week baseline period followed by randomization to an 8-week medication condition that included 1 hour per week of cognitive behavioral drug counseling. A safety evaluation was conducted 4 weeks after termination. Measures : Outcomes included cocaine metabolites measured in urine, retention and self-reports for drug use, cocaine craving, clinical improvement, mood and HIV risk behaviors. Results : Participants assigned to receive cabergoline provided more urine samples negative for cocaine metabolites (42.4%) than those assigned to receive placebo (25.0%), a statistically significant difference after controlling for baseline differences in self-reported cocaine use (F = 2.95, df = 3; P = 0.05). Cabergoline-treated participants demonstrated a significant improvement over placebo from baseline to week 8 when measured using the Addiction Severity Index (ASI) employment subscale (overall change = {PRIVATE "TYPE=PICT;ALT=-"}0.09, SD = 0.10, t = 2.36, P
Affiliation :
UCLA/Integrated Substance Abuse Programs 11075 Santa Monica Blvd Suite 200 Los Angeles CA 90025 ; Sshoptaw@mednet.ucla.edu
Etats-Unis. United States.
Etats-Unis. United States.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |